CD274 and non-small cell lung carcinoma: Recently, a phase 2 trial of administering 2 cycles of atezolizumab, an anti-PD-L1 monoclonal antibody in neoadjuvant setting for resectable stage IB-IIIB NSCLC, yielded clinically meaningful major pathologic response rate of 20%27.